Search research articles
Contact Us
Filters
Showing results (131-140 of 142) with videos related to
Page
of 15
Sort By:
The Lancet. Oncology
|
August 11, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, et al.
Breast Cancer Research and Treatment
|
December 19, 2023
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Judith Balmaña, Peter A Fasching, Fergus J Couch, et al.
American Journal of Obstetrics and Gynecology
|
October 6, 2024
FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia
Adrien Msika, Virginie Mathias, Marina Boudigou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Yvette Drew, Jae-Weon Kim, Richard T Penson, et al.
Translational Oncology
|
July 1, 2026
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial
Pauline Corbaux, Olivier Colomban, Gaelle Lescuyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
Udai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.
Nature Communications
|
August 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Florence Joly, Alexandra Leary, Isabelle Ray-Coquard, et al.
Nature Medicine
|
January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
Nature Cancer
|
June 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial
Edith Borcoman, Bastien Cabarrou, Miguel Francisco, et al.
Nature
|
September 7, 2022
Genomics to select treatment for patients with metastatic breast cancer
Fabrice Andre, Thomas Filleron, Maud Kamal, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 142) with videos related to
Sort By:
Page
of 15
The Lancet. Oncology
|
August 11, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, et al.
Breast Cancer Research and Treatment
|
December 19, 2023
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Judith Balmaña, Peter A Fasching, Fergus J Couch, et al.
American Journal of Obstetrics and Gynecology
|
October 6, 2024
FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia
Adrien Msika, Virginie Mathias, Marina Boudigou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Yvette Drew, Jae-Weon Kim, Richard T Penson, et al.
Translational Oncology
|
July 1, 2026
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial
Pauline Corbaux, Olivier Colomban, Gaelle Lescuyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
Udai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.
Nature Communications
|
August 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Florence Joly, Alexandra Leary, Isabelle Ray-Coquard, et al.
Nature Medicine
|
January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
Nature Cancer
|
June 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial
Edith Borcoman, Bastien Cabarrou, Miguel Francisco, et al.
Nature
|
September 7, 2022
Genomics to select treatment for patients with metastatic breast cancer
Fabrice Andre, Thomas Filleron, Maud Kamal, et al.
Page
of 15